Mar 24 / 2021

AstraZeneca embraces digital technology to manage and treat chronic diseases

AstraZeneca turns to digital technology with Amaze in bid to help patients and clinicians manage and treat chronic conditions

AstraZeneca is pushing forward with digital approach to treating and managing chronic diseases with Amaze in bid to help patients and clinicians. The company has stressed that they believe digital tools will become the future of care.

The company envisions a future where patients with a chronic condition will receive perceptions for two products. The first will be the medication that treats the disease, and the other will be for the digital technology that informs clinicians about the medication, potential side effects, and whether the patient is recovering or not.

Karan Arora
Karan Arora contends that the company believes in the longevity of digital technologies for chronic disease management.

Karan Arora, chief commercial digital officer and global vice president at AstraZeneca, shared to MedCity News the current challenges faced by clinicians when it comes to managing chronic illness:

There’s a massive data gap,

When you’re discharged, the clinician has no clue how to manage your health.

The pharmaceutical giant is looking to fill in those gaps by employing digital technology. The company launched Amaze, an easy to use smartphone app that logs patient data, contributing to the number of companies bringing digital health into patient’s homes. At the moment, the software-as-a-service offering is focussing on asthma and heart failure. However, AstraZeneca is planning to expand into diabetes, kidney disorders, and chronic obstructive pulmonary disease.

AstraZeneca is distributing Amaze through its connections to healthcare providers.

Arora commented on Amaze stating:

Given the pandemic, you can imagine patients are showing up less at the hospital,

And post discharge, patients are trying to manage their conditions at home. You’re going to see digital become more the standard of care.

Source: MedCity News

Share this entry: gplus-button facebook-button linkedin-button twitter-button
or go back to NEWS page